Overview

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Phase:

N/A

Details

Lead Sponsor:

Kevin H.M. Kuo, MD, MSc, FRCPC

Treatments:

Amlodipine
Calcium Channel Blockers
Deferasirox
Iron